Combination Therapy of a type II anti-cd20 Antibody with Active Anti - Bcl - 2

摘要

The present Invention relates to the use of a type II anti-cd20 Antibody for the manufacture of a Medicament for the treatment of cancer, especially cancers that express the CD20, in combination with Active Anti - Bcl - 2.Use according to claim 4: any one of claims 1 to 3, wherein the type II anti-cd20 Antibody is an Antibody (LY1 Humanized.Use according to claim 7: any one of claims 1 to 6, wherein the active Agent anti Bcl - 2 is chosen from the group formed by the SPC Oblimersen, 2996, RTA 402, gossypol, AT 101, obatoclax Mesylate, 371191 385358 -, -, - 438744, abt-737, AT 101 - 11, BL, BL - 193 GX - 15 - 003, 2 - metoxiantimicina A3 has - 1, - 14, - 67544 KF, purpurogalina, TP - TW - 37, YC - and Z - 137 24With Preference between the group formed by the abt-263 and abt-737.